Terms: = Skin cancer AND HER1, YOR227W AND Clinical Outcome
4 results:
1. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Bianchini D; Jayanth A; Chua YJ; Cunningham D
Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
[TBL] [Abstract] [Full Text] [Related]
2. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response.
Brandt B; Meyer-Staeckling S; Schmidt H; Agelopoulos K; Buerger H
Clin Cancer Res; 2006 Dec; 12(24):7252-60. PubMed ID: 17189396
[TBL] [Abstract] [Full Text] [Related]
3. Cutaneous adverse effects with her1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R; Saltz L
J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
[TBL] [Abstract] [Full Text] [Related]
4. her1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the her1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract] [Full Text] [Related]
